Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.58 |
| ▸ | CNR1 | P21554 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8352815 | 1.00 | CNR2 (0.58) | CNR2CNR1KMT2APDE4APDE4B | |
| SCHEMBL8352785 | 0.88 | CNR1 (0.59) | CNR2CNR1KMT2APDE4APDE4B | |
| SCHEMBL8351097 | 0.88 | CNR1 (0.59) | CNR2CNR1KMT2APDE4APDE4B | |
| Hydrochloric Acid SCHEMBL6063567 | 0.87 | CNR1 (0.58) | CNR2CNR1KMT2APDE4APDE4B | |
| SCHEMBL6063263 | 0.87 | CNR1 (0.58) | CNR2CNR1KMT2APDE4APDE4B | |
| SCHEMBL5839447 | 0.86 | CNR2 (0.50) | CNR2CNR1L3MBTL1 | |
| SCHEMBL5839441 | 0.86 | CNR2 (0.50) | CNR2CNR1L3MBTL1 | |
| SCHEMBL6063424 | 0.85 | CNR2 (0.59) | CNR2CNR1KMT2A | |
| SCHEMBL8352455 | 0.85 | CNR2 (0.59) | CNR2CNR1KMT2A | |
| SCHEMBL8352461 | 0.85 | PDE4B (0.59) | CNR2CNR1PDE4APDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7060717-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC (US) | 2006-06-13 | — | — | US | disclosed |
| US-20060014780-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC | 2006-01-19 | — | — | US | disclosed |
| US-6949573-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1476158-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-20040224975-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. | 2004-11-11 | — | — | US | disclosed |
| US-20030220361-A1 | Administering together tiotropium salt and substituted 3-amidopyridine derivatives for treating inflammation, allergic and respiratory diseases | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| US-20030220366-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003068235-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014780-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | CNR2 1090/4885CNR1 1648/4885KMT2A 2770/4885 |
| US-20030220361-A1 | Administering together tiotropium salt and substituted 3-amidopyridine derivatives for treating inflammation, allergic and respiratory diseases | NNT, IL5, NOX5 | CNR2 284/4885CNR1 576/4885KMT2A 2623/4885 |
| US-20040224975-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | CNR2 1090/4885CNR1 1648/4885KMT2A 2770/4885 |
| US-20030220366-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | CNR2 1090/4885CNR1 1648/4885KMT2A 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.